İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi

AYDIN, Nasuhi Engin; EDALI, Naci; USTA, Ufuk

İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi

Ufuk USTA, (Trakya Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Edirne, Türkiye)

Naci EDALI, (İnönü Üniversitesi, Tıp Fakültesi, Malatya, Türkiye)

Nasuhi Engin AYDIN (İnönü Üniversitesi, Tıp Fakültesi, Malatya, Türkiye)

Trakya Üniversitesi Tıp Fakültesi Dergisi

303 1

Yıl: 2007 Cilt: 24 Sayı: 1 Sayfa Aralığı: 28 - 35 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi

Öz:

Amaç: Proliferatif ve atrofik endometriyumda ve farklı endometriyal patolojilerde, proliferatif ve apopitotik mekanizmaların rolü immünohistokimyasal yöntemlerle araştırıldı.Hastalar ve Yöntemler: Arşivden seçilen 13'ü endometriyoid karsinom, sekizi endometriyal hiperplazi, 15'i düzensiz proliferasyon, 12'si proliferatif endometriyum ve yedisi atrofik/ inaktif endometriyum olmak üzere toplam 55 olgu çalışmaya alındı. Olguların her birinden seçilen tanısal bloklardan alınan kesitlere immünohistokimyasal olarak bir antiapopitotik belirleyici olan bcl-2 ve proliferasyon belirleyicisi olarak Ki-67 boyası uygulandı. Ayrıca hiperplazi ve endometriyoid karsinom olgularında 10 büyük büyütme alanında mitoz sayıldı.Bulgular: Bcl-2 reaksiyonu için H-skor değerlerinin ortalaması endometriyoid karsinom olguları için 0.48 olarak bulundu. Hiperplazi, düzensiz proliferasyon, proliferasyon ve atrofi olgularında ise H-skor ortalama değerleri sırasıyla 1.93, 1.62, 1.5 ve 1.0 olarak hesaplandı. Endometriyoid karsinom olguları için Ki-67 indeksi %48.9 olarak hesaplandı. Bu indeks hiperplazi, düzensiz proliferasyon, proliferasyon ve atrofi olgularında sırasıyla %32, %29, %31.5 ve %8.4 olarak bulundu.Sonuç: Bcl-2 boyanmasının en yüksek düzeylere hiperplazi olgularında eriştiği, buna karşılık, boyanmanın hiperplazilerde atipinin belirginleşmesi ile beraber azaldığı görüldü ve en zayıf boyanmanın derece II ve III endometriyoid karsinomlarda oluştuğu izlendi. Buna karşılık proliferatif indeksin karsinom derecesi ile birlikte arttığı görüldü.

Anahtar Kelime: Hiperplazi Karsinom, endometroid Genler, bcl-2 Ki-67 antijeni Endometriyum hiperplazisi İmmünohistokimya

Konular: Patoloji

Evaluation of proliferative-apoptotic activity in inactive, proliferative, hyperplastic endometria and endometrioid carcinomas

Öz:

Objectives: The role of proliferative and apoptotic mechanisms in various endometrial pathologies and in proliferative and atrophic endometria was assessed by immunohistochemical methods.Patients and Methods: A total of 55 cases consisting of 13 endometrioid carcinomas, eight cases of endometrial hyperplasia, 15 cases of disordered proliferation, 12 cases with proliferative and seven with inactive/athrophic endometria gathered from the local archives were included in the study. Immunohistochemical markers and stains, namely bcl-2, an antiapopitotic marker, and Ki-67, a proliferative marker were applied to the sections of selected diagnostic tissue blocks. Additionally, mitotic counts per 10 high power fields were obtained in cases of hyperplasia and carcinoma.Results: Mean H-score value for bcl-2 reaction was 0.48 for endometrioid carcinoma. Mean H-score values for cases of hyperplasia, disordered proliferation, proliferation and atrophy were calculated as 1.93, 1.62, 1.5 and 1.0, respectively. Ki-67 proliferation index for endometrioid carcinoma was 48.9%. This index was 32%, 29%, 31.5% and 8.4% for hyperplasia, disordered proliferation, proliferation and atrophy, respectively.Conclusion: Staining with bcl–2 peaked in cases of hyperplasia, and lost its intensity as nuclear atypia became evident. Weakest staining was observed in cases with grade II and III endometrioid carcinomas. In contrast, proliferative indexes increased with increasing grades of carcinoma.

Anahtar Kelime: Endometrial Hyperplasia Immunohistochemistry Hyperplasia Carcinoma, Endometrioid Genes, bcl-2 Ki-67 Antigen

Konular: Patoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1) Ronnett BM, Zaino RJ, Ellenson LH, Kurman RJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 5th ed. New York: Springer-Verlag; 2002. p. 501- 61.
2) Rosai J. Female reproductive system. In: Rosai J, editor. Rosai and ackerman's surgical pathology. St Louis: Mosby-Year Book; 2004. p. 1569- 635.
3) Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13:295-308.
4) Al Kushi A, Lim P, Aquino-Parsons C, Gilks CB. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 2002;15:365-71.
5) Morsi HM, Leers MP, Jager W, Bjorklund V, Radespiel-Troger M, el Kabarity H, et al. The patterns of expression of an apoptosis-related CK18 neoepitope, the bcl-2 proto-oncogene, and the Ki67 proliferation marker in normal, hyperplastic, and malignant endometrium. Int J Gynecol Pathol 2000; 19:118-26.
6) Sakuragi N, Ohkouchi T, Hareyama H, Ikeda K, Watari H, Fujimoto T, et al. Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int J Cancer 1998;79:153-8.
7) Miturski R, Semczuk A, Tomaszewski J, Jakowicki J. bcl-2 protein expression in endometrial carcinoma: the lack of correlation with p53. Cancer Lett 1998; 133:63-9.
8) Taskin M, Lallas TA, Barber HR, Shevchuk MM. bcl- 2 and p53 in endometrial adenocarcinoma. Mod Pathol 1997;10:728-34.
9) Cinel L, Polat A, Aydin O, Dusmez D, Egilmez R. Bcl-2, iNOS, p53 and PCNA expression in normal, disordered proliferative, hyperplastic and malignant endometrium. Pathol Int 2002;52:384-9.
10) Castro A, Johnson MC, Anido M, Cortinez A, Gabler F, Vega M. Role of nitric oxide and bcl-2 family genes in the regulation of human endometrial apoptosis. Fertil Steril 2002;78:587-95.
11) Giuffre G, Fulcheri E, Gualco M, Fedele F, Tuccari G. Standardized AgNOR analysis as a prognostic parameter in endometrial carcinoma, endometrioid type. Anal Quant Cytol Histol 2001;23:31-9.
12) Ikawa S, Sano T, Furumoto H, Aono T. Multidirectional differentiation of endometrial carcinoma with special reference to tumor aggressiveness evaluated by Ki-67 expression. Gynecol Oncol 1999; 72:323-30.
13) Dahmoun M, Boman K, Cajander S, Westin P, Backstrom T. Apoptosis, proliferation, and sex hormone receptors in superficial parts of human endometrium at the end of the secretory phase. J Clin Endocrinol Metab 1999;84:1737-43.
14) Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-26
15) Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993;341:1251-4.
16) Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998;29:1150-9.
17) von Rango U, Classen-Linke I, Krusche CA, Beier HM. The receptive endometrium is characterized by apoptosis in the glands. Hum Reprod 1998;13:3177-89.
18) Coppola D, Fu L, Nicosia SV, Kounelis S, Jones M. Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma. Hum Pathol 1998;29:455-62.
19) Saegusa M, Okayasu I. Down-regulation of bcl-2 expression is closely related to squamous differentiation and progesterone therapy in endometrial carcinomas. J Pathol 1997;182:429-36.
20) Nunez G, Clarke MF. The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol 1994;4:399-403.
21) Osborne BA, Schwartz LM. Essential genes that regulate apoptosis. Trends Cell Bio 1994;4:394-9.
22) Crescenzi E, Palumbo G. Bcl-2 exerts a pRb-mediated cell cycle inhibitory function in HEC1B endometrial carcinoma cells. Gynecol Oncol 2001;81:184-92.
23) Dabbs DJ, editor. Diagnostic immunohistochemistry. Philadelphia: Churchill Livingstone; 2002.
24) Niemann TH, Trgovac TL, McGaughy VR, Vaccarello L. bcl-2 expression in endometrial hyperplasia and carcinoma. Gynecol Oncol 1996;63:318-22.
25) Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch 2001;438:470-7.
26) Athanassiadou P, Petrakakou E, Liossi A, Nakopoulou L, Zerva C, Dimopoulos A, et al. Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium. Acta Cytol 1999; 43:1039-44.
27) Milde-Langosch K, Bamberger AM, Goemann C, Rossing E, Rieck G, Kelp B, et al. Expression of cellcycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 2001;127:537-44.
28) Toki T, Horiuchi A, Li SF, Nakayama K, Silverberg SG, Fujii S. Proliferative activity of postmenopausal endometriosis: a histopathologic and immunocyto- chemical study. Int J Gynecol Pathol 1996;15:45-53.
29) Ambros RA. Simple hyperplasia of the endometrium: an evaluation of proliferative activity by Ki- 67 immunostaining. Int J Gynecol Pathol 2000; 19:206-11.
30) Salvesen HB, Iversen OE, Akslen LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 1998;4:2779-85.
31) Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999;17:1382-90.
32) Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000;6:153-9.
33) Aksoy F, Seçkin S, Günçe S, Ergül G. Endometriumda hiperplazi ve adenokarsinoma olgularında PCNA ve Ki-67 ile proliferatif aktivite. Ankara Patoloji Bülteni 1998;15:16-8.

APA	USTA U, EDALI N, AYDIN N (2007). İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi. , 28 - 35.
Chicago	USTA Ufuk,EDALI Naci,AYDIN Nasuhi Engin İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi. (2007): 28 - 35.
MLA	USTA Ufuk,EDALI Naci,AYDIN Nasuhi Engin İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi. , 2007, ss.28 - 35.
AMA	USTA U,EDALI N,AYDIN N İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi. . 2007; 28 - 35.
Vancouver	USTA U,EDALI N,AYDIN N İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi. . 2007; 28 - 35.
IEEE	USTA U,EDALI N,AYDIN N "İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi." , ss.28 - 35, 2007.
ISNAD	USTA, Ufuk vd. "İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi". (2007), 28-35.

APA	USTA U, EDALI N, AYDIN N (2007). İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi. Trakya Üniversitesi Tıp Fakültesi Dergisi, 24(1), 28 - 35.
Chicago	USTA Ufuk,EDALI Naci,AYDIN Nasuhi Engin İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi. Trakya Üniversitesi Tıp Fakültesi Dergisi 24, no.1 (2007): 28 - 35.
MLA	USTA Ufuk,EDALI Naci,AYDIN Nasuhi Engin İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi. Trakya Üniversitesi Tıp Fakültesi Dergisi, vol.24, no.1, 2007, ss.28 - 35.
AMA	USTA U,EDALI N,AYDIN N İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi. Trakya Üniversitesi Tıp Fakültesi Dergisi. 2007; 24(1): 28 - 35.
Vancouver	USTA U,EDALI N,AYDIN N İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi. Trakya Üniversitesi Tıp Fakültesi Dergisi. 2007; 24(1): 28 - 35.
IEEE	USTA U,EDALI N,AYDIN N "İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi." Trakya Üniversitesi Tıp Fakültesi Dergisi, 24, ss.28 - 35, 2007.
ISNAD	USTA, Ufuk vd. "İnaktif, proliferatif, hiperplazik endometriyumlarda ve endometriyoid karsinomda proliferatif-apopitotik aktivitenin değerlendirilmesi". Trakya Üniversitesi Tıp Fakültesi Dergisi 24/1 (2007), 28-35.